Torley Heleninsider trades
In SEC Form 4 filings, Torley Helen is listed as PRESIDENT AND CEO of Halozyme Therapeutics, Inc. (HALO). In the last 90 days, Torley Helen sold $13.05M of Halozyme Therapeutics, Inc. (HALO) on the open market and bought none. All 19 sales were reported under a 10b5-1 trading plan.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| HALOHalozyme Therapeutics, Inc. | PRESIDENT AND CEO | 31 | Oct 8 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-11
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| HALOHalozyme Therapeutics, Inc. | Oct 8 | Oct 8 | M | 20,000 | $18.41 | $368,200 | 787,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 8 | Oct 8 | S | 4,810 | $108.18 | Sale −$520,341 | 782,970 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 8 | Oct 8 | S | 3,090 | $108.91 | Sale −$336,526 | 779,880 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 8 | Oct 8 | S | 11,900 | $110.00 | Sale −$1,308,941 | 767,980 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 8 | Oct 8 | S | 200 | $110.51 | Sale −$22,102 | 767,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 8 | Oct 8 | M · derivative | 20,000 | $18.41 | $368,200 | 21,552 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 7 | Oct 8 | M | 20,000 | $18.41 | $368,200 | 787,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 7 | Oct 8 | S | 8,600 | $111.03 | Sale −$954,867 | 779,180 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 7 | Oct 8 | S | 10,300 | $111.84 | Sale −$1,151,942 | 768,880 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 7 | Oct 8 | S | 900 | $112.78 | Sale −$101,502 | 767,980 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 7 | Oct 8 | S | 200 | $113.69 | Sale −$22,739 | 767,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 7 | Oct 8 | M · derivative | 20,000 | $18.41 | $368,200 | 41,552 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 6 | Oct 8 | M | 20,000 | $18.41 | $368,200 | 787,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 6 | Oct 8 | S | 2,300 | $107.90 | Sale −$248,175 | 785,480 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 6 | Oct 8 | S | 6,000 | $109.33 | Sale −$656,004 | 779,480 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 6 | Oct 8 | S | 9,920 | $109.89 | Sale −$1,090,119 | 769,560 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 6 | Oct 8 | S | 1,780 | $110.81 | Sale −$197,245 | 767,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Oct 6 | Oct 8 | M · derivative | 20,000 | $18.41 | $368,200 | 61,552 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 11 | Sep 11 | M | 20,000 | $18.41 | $368,200 | 787,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 11 | Sep 11 | S | 15,492 | $107.15 | Sale −$1,660,030 | 772,288 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 11 | Sep 11 | S | 4,508 | $107.55 | Sale −$484,826 | 767,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 11 | Sep 11 | M · derivative | 20,000 | $18.41 | $368,200 | 81,552 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 10 | Sep 11 | M | 20,000 | $18.41 | $368,200 | 787,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 10 | Sep 11 | S | 14,588 | $107.01 | Sale −$1,561,091 | 773,192 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 10 | Sep 11 | S | 5,412 | $107.58 | Sale −$582,228 | 767,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 10 | Sep 11 | M · derivative | 20,000 | $18.41 | $368,200 | 101,552 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 9 | Sep 11 | M | 20,000 | $18.41 | $368,200 | 787,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 9 | Sep 11 | S | 13,304 | $107.22 | Sale −$1,426,481 | 774,476 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 9 | Sep 11 | S | 6,596 | $107.82 | Sale −$711,187 | 767,880 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 9 | Sep 11 | S | 100 | $108.67 | Sale −$10,867 | 767,780 | Yes | Form 4 |
| HALOHalozyme Therapeutics, Inc. | Sep 9 | Sep 11 | M · derivative | 20,000 | $18.41 | $368,200 | 121,552 | Yes | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.